Click it and Unblock the Notifications
Just In
Don't Miss
-
KKR vs RR Memes: Fans Take Potshot at KKR for Conceding Match after Scoring 223; Praises Jos Buttler's Knock -
Dr Sarvepalli Radhakrishnan Death Anniversary: Profound And Inspiring Quotes For Students -
Rs 7/Share Dividend: May 3 Fixed As Record Date; Buy The Large Cap Stock To Be Eligible? -
Bade Miyan Chote Miyan Vs Maidaan Box Office Collection Day 6: Akshay Kumar BEATS Ajay Devgn. Margin Is... -
UPSC Success Story: An IITian, A Government Job Holder at Railways, Quit the Job and Emerged as an IAS -
Jeep Compass Gets More Powerful 268.3bhp Turbo Petrol Engine – Check Out All The Details Here -
Redmi Pad SE With 90Hz Display Launching on April 23 in India; Could Be Priced for Less Than Rs 20,000 -
From Coconut Breaking on Head to Men Dressing as Women: 12 Unique Indian Rituals Explored
COVID-19 Vaccine: Nepal gives emergency use approval to Bharat Biotech's Covaxin
Kathmandu, Mar 20: Nepal''s national drug regulatory authority on Saturday granted emergency use approval to Bharat Biotech''s Covaxin, becoming the third country to approve India''s indigenously developed COVID-19 vaccine.
A meeting of the drug advisory committee of the Department of Drug Administration decided to issue a conditional emergency use authorisation to India''s homegrown government-backed vaccine Covaxin, the third COVID-19 vaccine authorised in the country,The Kathmandu Post reported.
COVAXIN, which demonstrated an interim vaccine efficacy of 81 per cent in the Phase 3 clinical trials India, was approved for emergency use in India in January and Zimbabwe cleared it early this month.
Bharat Biotech had applied for emergency use authorisation for its vaccine in Nepal on January 13. Of the three applications filed on January 13, the department had first granted emergency use authorisation to Oxford-AstraZeneca on January 15.
The AstraZeneca vaccine, manufactured by the Serum Institute of India under the name of Covishiled, was then accordingly brought to the country.
Nepal granted emergency use authorisation to BBIBP-CorV vaccine, developed by China's Sinopharm on February 17.
Emergency use authorisation (EUA) is granted for some drugs and vaccines by authorities during a declared emergency when officials can make a judgment that the drug is worth releasing, even without all the evidence that would fully establish its effectiveness and safety.
Such a decision is taken when there's enough evidence to suggest that patients have benefitted from the drug/vaccine.
Nepal has used one million doses of AstraZeneca vaccines provided by India in January under grant assistance in sync with its 'Neighbourhood First' policy. It is now also awaiting another consignment of 2 million AstraZeneca vaccines from the Serum Institute of India (SII).
The latest approval comes as authorities in Nepal said they were suspending their vaccination campaign because of a lack of supply.
Nepal has reported 275,750 cases and 3,016 deaths so far, according to government data.
